Citizens Maintains Market Outperform on Microbot Medical, Lowers Price Target to $2

Benzinga · 1d ago
Citizens analyst Daniel Stauder maintains Microbot Medical (NASDAQ:MBOT) with a Market Outperform and lowers the price target from $2.5 to $2.